{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:26:43Z","timestamp":1757618803370,"version":"3.44.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-025-03190-9","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T21:15:21Z","timestamp":1752527721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integration of Design of Experiments for the Development and Evaluation of Sulfasalazine Loaded Hybrid Albumin Chitosan Based Polymeric Nanocarriers"],"prefix":"10.1208","volume":"26","author":[{"given":"Sushrut","family":"Marathe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongbing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gauri","family":"Shadambikar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 S.","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9879-4344","authenticated-orcid":false,"given":"Mahavir Bhupal","family":"Chougule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"3190_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2020.05.010","volume":"136","author":"L Moreno","year":"2020","unstructured":"Moreno L, Barone G, DuBois SG, Molenaar J, Fischer M, Schulte J, et al. Accelerating drug development for neuroblastoma: summary of the second neuroblastoma drug development strategy forum from innovative therapies for children with cancer and International Society of Paediatric Oncology Europe Neuroblastoma. Eur J Cancer. 2020;136:52\u201368.","journal-title":"Eur J Cancer"},{"key":"3190_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-015-1447-y","volume":"15","author":"LP Yco","year":"2015","unstructured":"Yco LP, Geerts D, Mocz G, Koster J, Bachmann AS. Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target. BMC Cancer. 2015;15:1\u201311.","journal-title":"BMC Cancer"},{"key":"3190_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.bcp.2019.01.007","volume":"162","author":"MR Mooney","year":"2019","unstructured":"Mooney MR, Geerts D, Kort EJ, Bachmann AS. Anti-tumor effect of sulfasalazine in neuroblastoma. Biochem Pharmacol. 2019;162:237\u201349.","journal-title":"Biochem Pharmacol"},{"key":"3190_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nchembio.557","volume":"7","author":"C Chidley","year":"2011","unstructured":"Chidley C, Haruki H, Pedersen MG, Muller E, Johnsson K. A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis. Nat Chem Biol. 2011;7:375\u201383.","journal-title":"Nat Chem Biol"},{"issue":"340","key":"3190_CR5","first-page":"987","volume":"2013","author":"H Haruki","year":"1979","unstructured":"Haruki H, Pedersen MG, Gorska KI, Pojer F, Johnsson K. Tetrahydrobiopterin biosynthesis as an off-target of sulfa drugs. Science. 1979;2013(340):987\u201391.","journal-title":"Science"},{"key":"3190_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.coph.2011.10.019","volume":"12","author":"M Costigan","year":"2012","unstructured":"Costigan M, Latremoliere A, Woolf CJ. Analgesia by inhibiting tetrahydrobiopterin synthesis. Curr Opin Pharmacol. 2012;12:92\u20139.","journal-title":"Curr Opin Pharmacol"},{"key":"3190_CR7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.molstruc.2004.10.093","volume":"744","author":"A Su\u0142kowska","year":"2005","unstructured":"Su\u0142kowska A, R\u00f3wnicka J, Po\u017cycka J, Bojko B, Su\u0142kowski WW. The effect of concentration of guanidine hydrochloride on the sulfasalazine\u2013serum albumin complex. J Mol Struct. 2005;744:775\u20139.","journal-title":"J Mol Struct"},{"key":"3190_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.molstruc.2008.12.053","volume":"924","author":"J R\u00f3wnicka-Zubik","year":"2009","unstructured":"R\u00f3wnicka-Zubik J, Su\u0142kowska A, Po\u017cycka J, Ga\u017adzicka K, Bojko B, Maci\u0105\u017cek-Jurczyk M, et al. Fluorescence analysis of sulfasalazine bound to defatted serum albumin in the presence of denaturating factors. J Mol Struct. 2009;924:371\u20137.","journal-title":"J Mol Struct"},{"key":"3190_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.16","volume":"34","author":"HA Bird","year":"1995","unstructured":"Bird HA. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid\u2014which is the active moiety in rheumatoid arthritis? Rheumatology. 1995;34:16\u20139.","journal-title":"Rheumatology"},{"key":"3190_CR10","doi-asserted-by":"publisher","first-page":"7184","DOI":"10.1016\/S0021-9258(19)66953-X","volume":"252","author":"JK Iglehart","year":"1977","unstructured":"Iglehart JK, York RM, Modest AP, Lazarus H, Livingston DM. Cystine requirement of continuous human lymphoid cell lines of normal and leukemic origin. J Biol Chem. 1977;252:7184\u201391.","journal-title":"J Biol Chem"},{"key":"3190_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/jcp.1041070215","volume":"107","author":"T Ishii","year":"1981","unstructured":"Ishii T, Hishinuma I, Bannai S, Sugita Y. Mechanism of growth promotion of mouse lymphoma L1210 cells in vitro by feeder layer or 2-mercaptoethanol. J Cell Physiol. 1981;107:283\u201393.","journal-title":"J Cell Physiol"},{"key":"3190_CR12","doi-asserted-by":"crossref","unstructured":"ECK, Hans-Peter and DR\u00d6GE, Wulf. \"Influence of the extracellular glutamate concentration on the intracellular cyst(e)ine concentration in macrophages and on thecapacity to release cysteine\". Biol Chem. 1989;370(1):109\u2013114.","DOI":"10.1515\/bchm3.1989.370.1.109"},{"key":"3190_CR13","doi-asserted-by":"crossref","unstructured":"Helmut Gm\u00fcnder, Hans-Peter Eck, Bernd Benninghoff, Steffen Roth, Wulf Dr\u00f6ge, Macrophages regulate intracellular glutathione levels of lymphocytes. Evidence for an immunoregulatory role of cysteine. Cell Immunol. 129;(1):32\u201346.","DOI":"10.1016\/0008-8749(90)90184-S"},{"key":"3190_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/jcp.1041120216","volume":"112","author":"S Bannai","year":"1982","unstructured":"Bannai S, Ishii T. Transport of cystine and cysteine and cell growth in cultured human diploid fibroblasts: effect of glutamate and homocysteate. J Cell Physiol. 1982;112:265\u201372.","journal-title":"J Cell Physiol"},{"key":"3190_CR15","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/sj.leu.2402238","volume":"15","author":"PW Gout","year":"2001","unstructured":"Gout PW, Buckley AR, Simms CR, Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc\u2212 cystine transporter: a new action for an old drug. Leukemia. 2001;15:1633\u201340.","journal-title":"Leukemia"},{"key":"3190_CR16","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jmb.2013.09.037","volume":"426","author":"I Lange","year":"2014","unstructured":"Lange I, Geerts D, Feith DJ, Mocz G, Koster J, Bachmann AS. Novel interaction of ornithine decarboxylase with sepiapterin reductase regulates neuroblastoma cell proliferation. J Mol Biol. 2014;426:332\u201346.","journal-title":"J Mol Biol"},{"key":"3190_CR17","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.7314\/APJCP.2014.15.16.6939","volume":"15","author":"H-Y Han","year":"2014","unstructured":"Han H-Y, Kim H, Jeong S-H, Lim D-S, Ryu MH. Sulfasalazine induces autophagic cell death in oral cancer cells via Akt and ERK pathways. Asian Pac J Cancer Prev. 2014;15:6939\u201344.","journal-title":"Asian Pac J Cancer Prev"},{"key":"3190_CR18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.7150\/ijms.30380","volume":"16","author":"C-W Wei","year":"2019","unstructured":"Wei C-W, Yu Y-L, Lu J-Y, Hung Y-T, Liu H-C, Yiang G-T. Anti-cancer effects of sulfasalazine and vitamin E succinate in MDA-MB 231 triple-negative breast cancer cells. Int J Med Sci. 2019;16:494.","journal-title":"Int J Med Sci"},{"key":"3190_CR19","first-page":"3517","volume":"18","author":"L Zou","year":"2019","unstructured":"Zou L, Gao Z, Zeng F, Xiao J, Chen J, Feng X, et al. Sulfasalazine suppresses thyroid cancer cell proliferation and metastasis through T-cell originated protein kinase. Oncol Lett. 2019;18:3517\u201326.","journal-title":"Oncol Lett"},{"key":"3190_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/cdd.2015.158","volume":"23","author":"Y Xie","year":"2016","unstructured":"Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369\u201379.","journal-title":"Cell Death Differ"},{"key":"3190_CR21","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1292\/jvms.22-0525","volume":"85","author":"H Itoh","year":"2023","unstructured":"Itoh H, Tani K, Sunahara H, Nemoto Y, Nakaichi M, Horikirizono H, et al. Sulfasalazine, a potent cystine-glutamate transporter inhibitor, enhances osteogenic differentiation of canine adipose-derived stem cells. J Vet Med Sci. 2023;85:1237\u201344.","journal-title":"J Vet Med Sci"},{"key":"3190_CR22","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1021\/acsbiomaterials.3c01223","volume":"10","author":"D Zhang","year":"2023","unstructured":"Zhang D, Zhang M, Pang Y, Li M, Ma W. Folic Acid-Modified Long-Circulating Liposomes Loaded with Sulfasalazine For Targeted Induction of Ferroptosis in Melanoma. ACS Biomater Sci Eng. 2023;10:588\u201398.","journal-title":"ACS Biomater Sci Eng"},{"key":"3190_CR23","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.xphs.2024.02.019","volume":"113","author":"S Jadiya","year":"2024","unstructured":"Jadiya S, Upmanyu N, Sathiyanarayanan A, Jain V, Dubey R, Buwade P. Formulation and Development of Novel Sulfasalazine Bilayer Tablets for The Treatment of Arthritis Associated With IBD: In-vitro and In-vivo Investigations. J Pharm Sci. 2024;113:1919\u201326. https:\/\/doi.org\/10.1016\/j.xphs.2024.02.019.","journal-title":"J Pharm Sci"},{"key":"3190_CR24","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1039\/C6CS00636A","volume":"46","author":"S Behzadi","year":"2017","unstructured":"Behzadi S, Serpooshan V, Tao W, Hamaly MA, Alkawareek MY, Dreaden EC, et al. Cellular Uptake of Nanoparticles: Journey Inside the Cell. Chem Soc Rev. 2017;46:4218. https:\/\/doi.org\/10.1039\/C6CS00636A.","journal-title":"Chem Soc Rev"},{"key":"3190_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1517\/17425255.2012.637916","volume":"8","author":"A Sharma","year":"2011","unstructured":"Sharma A, Madhunapantula SV, Robertson GP. Toxicological considerations when creating nanoparticle based drugs and drug delivery systems? Expert Opin Drug Metab Toxicol. 2011;8:47. https:\/\/doi.org\/10.1517\/17425255.2012.637916.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3190_CR26","doi-asserted-by":"crossref","unstructured":"Helmut Gm\u00fcnder, Hans-Peter Eck, Bernd Benninghoff, Steffen Roth, Wulf Dr\u00f6ge, Macrophages regulate intracellular glutathione levels of lymphocytes. Evidence for animmunoregulatory role of cysteine. Cell Immunol. 129;(1):32\u201346.","DOI":"10.1016\/0008-8749(90)90184-S"},{"key":"3190_CR27","first-page":"67","volume":"7","author":"J Maheshwara Rao","year":"2014","unstructured":"Maheshwara Rao J, Shyam Sunder R, Krishna SA. Formulation characterization and optimization of process variables of chitosan nanoparticles containing sulfasalazine. J Chem Pharm Sci. 2014;7:67\u201372.","journal-title":"J Chem Pharm Sci"},{"key":"3190_CR28","doi-asserted-by":"publisher","first-page":"11225","DOI":"10.1016\/j.ceramint.2017.05.172","volume":"43","author":"S Ghasemi","year":"2017","unstructured":"Ghasemi S, Farsangi ZJ, Beitollahi A, Mirkazemi M, Rezayat SM, Sarkar S. Synthesis of hollow mesoporous silica (HMS) nanoparticles as a candidate for sulfasalazine drug loading. Ceram Int. 2017;43:11225\u201332.","journal-title":"Ceram Int"},{"key":"3190_CR29","doi-asserted-by":"crossref","unstructured":"Tekade, R.K. and Chougule, M.B., 2013. Formulation development and evaluation of hybrid nanocarrier for cancer therapy: Taguchi orthogonal array based design. BioMed research international, 2013(1), p.712678.","DOI":"10.1155\/2013\/712678"},{"key":"3190_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/S10544-007-9139-2\/METRICS","volume":"10","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, Yang M, Portney NG, Cui D, Budak G, Ozbay E, et al. Zeta potential: A surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells. Biomed Microdevices. 2008;10:321\u20138. https:\/\/doi.org\/10.1007\/S10544-007-9139-2\/METRICS.","journal-title":"Biomed Microdevices"},{"key":"3190_CR31","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/mawe.200300699","volume":"34","author":"G Altankov","year":"2003","unstructured":"Altankov G, Richau K, Groth T. The role of surface zeta potential and substratum chemistry for regulation of dermal fibroblasts interaction. MaterWiss WerkstTech. 2003;34:1120\u20138. https:\/\/doi.org\/10.1002\/mawe.200300699.","journal-title":"MaterWiss WerkstTech"},{"key":"3190_CR32","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1021\/mp500403b","volume":"11","author":"RK Tekade","year":"2014","unstructured":"Tekade RK, Youngren-Ortiz SR, Yang H, Haware R, Chougule MB. Designing hybrid onconase nanocarriers for mesothelioma therapy: a Taguchi orthogonal array and multivariate component driven analysis. Mol Pharm. 2014;11:3671\u201383.","journal-title":"Mol Pharm"},{"key":"3190_CR33","doi-asserted-by":"publisher","unstructured":"Faisal MM, Gomaa E, Attia MS, Abdelnaby RM, Ibrahim AE, Al-Harrasi A, et al. Albumin-Based Nanoparticles with Factorial Design as a Promising Approach for Remodeled Repaglinide: Evidence from In Silico, In Vitro, and In Vivo Evaluations. Pharmaceutics 2025;17. https:\/\/doi.org\/10.3390\/pharmaceutics17030350.","DOI":"10.3390\/pharmaceutics17030350"},{"key":"3190_CR34","doi-asserted-by":"publisher","unstructured":"Mohammad-Beigi H, Shojaosadati SA, Morshedi D, Mirzazadeh N, Arpanaei A. The Effects of Organic Solvents on the Physicochemical Properties of Human Serum Albumin Nanoparticles. Iran J Biotechnol 2016;14:45\u201350. https:\/\/doi.org\/10.15171\/ijb.1168.","DOI":"10.15171\/ijb.1168"},{"key":"3190_CR35","doi-asserted-by":"publisher","unstructured":"Zieli\u0144ska A, Carreir\u00f3 F, Oliveira AM, Neves A, Pires B, Venkatesh DN, et al. Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. Molecules 2020;25. https:\/\/doi.org\/10.3390\/molecules25163731.","DOI":"10.3390\/molecules25163731"},{"key":"3190_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/712678","volume":"2013","author":"RK Tekade","year":"2013","unstructured":"Tekade RK, Chougule MB. Formulation development and evaluation of hybrid nanocarrier for cancer therapy: Taguchi orthogonal array based design. Biomed Res Int. 2013;2013: 712678. https:\/\/doi.org\/10.1155\/2013\/712678.","journal-title":"Biomed Res Int"},{"key":"3190_CR37","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1021\/mp500403b","volume":"11","author":"RK Tekade","year":"2014","unstructured":"Tekade RK, Youngren-Ortiz SR, Yang H, Haware R, Chougule MB. Designing hybrid onconase nanocarriers for mesothelioma therapy: a Taguchi orthogonal array and multivariate component driven analysis. Mol Pharm. 2014;11:3671\u201383. https:\/\/doi.org\/10.1021\/mp500403b.","journal-title":"Mol Pharm"},{"key":"3190_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2022.102915","volume":"39","author":"VR Shinde","year":"2022","unstructured":"Shinde VR, Revi N, Murugappan S, Singh SP, Rengan AK. Enhanced permeability and retention effect: A key facilitator for solid tumor targeting by nanoparticles. Photodiagnosis Photodyn Ther. 2022;39: 102915. https:\/\/doi.org\/10.1016\/j.pdpdt.2022.102915.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"3190_CR39","doi-asserted-by":"publisher","unstructured":"Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics 2018;10. https:\/\/doi.org\/10.3390\/pharmaceutics10020057.","DOI":"10.3390\/pharmaceutics10020057"},{"key":"3190_CR40","doi-asserted-by":"publisher","first-page":"9090325","DOI":"10.1155\/2017\/9090325","volume":"2017","author":"ST Jahan","year":"2017","unstructured":"Jahan ST, Sadat SMA, Walliser M, Haddadi A. Targeted Therapeutic Nanoparticles: An Immense Promise to Fight against Cancer. J Drug Deliv. 2017;2017:9090325. https:\/\/doi.org\/10.1155\/2017\/9090325.","journal-title":"J Drug Deliv"},{"key":"3190_CR41","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.2147\/IJN.S132780","volume":"12","author":"S Shen","year":"2017","unstructured":"Shen S, Wu Y, Liu Y, Wu D. High drug-loading nanomedicines: progress, current status, and prospects. Int J Nanomedicine. 2017;12:4085\u2013109. https:\/\/doi.org\/10.2147\/IJN.S132780.","journal-title":"Int J Nanomedicine"},{"key":"3190_CR42","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.2147\/DDDT.S88023","volume":"9","author":"MN Kundranda","year":"2015","unstructured":"Kundranda MN, Niu J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des Devel Ther. 2015;9:3767\u201377. https:\/\/doi.org\/10.2147\/DDDT.S88023.","journal-title":"Drug Des Devel Ther"},{"key":"3190_CR43","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/bs.apcsb.2014.12.002","volume":"98","author":"AO Elzoghby","year":"2015","unstructured":"Elzoghby AO, Elgohary MM, Kamel NM. Implications of protein- and Peptide-based nanoparticles as potential vehicles for anticancer drugs. Adv Protein Chem Struct Biol. 2015;98:169\u2013221. https:\/\/doi.org\/10.1016\/bs.apcsb.2014.12.002.","journal-title":"Adv Protein Chem Struct Biol"},{"key":"3190_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejps.2004.09.011","volume":"24","author":"U Bilati","year":"2005","unstructured":"Bilati U, All\u00e9mann E, Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci. 2005;24:67\u201375. https:\/\/doi.org\/10.1016\/j.ejps.2004.09.011.","journal-title":"Eur J Pharm Sci"},{"key":"3190_CR45","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s10930-016-9652-3","volume":"35","author":"DS Aniesrani Delfiya","year":"2016","unstructured":"Aniesrani Delfiya DS, Thangavel K, Amirtham D. Preparation of Curcumin Loaded Egg Albumin Nanoparticles Using Acetone and Optimization of Desolvation Process. Protein J. 2016;35:124\u201335. https:\/\/doi.org\/10.1007\/s10930-016-9652-3.","journal-title":"Protein J"},{"key":"3190_CR46","doi-asserted-by":"publisher","first-page":"16495","DOI":"10.1021\/acs.jpcc.9b00913","volume":"123","author":"HT Phan","year":"2019","unstructured":"Phan HT, Haes AJ. What Does Nanoparticle Stability Mean? J Phys Chem C Nanomater Interfaces. 2019;123:16495\u2013507. https:\/\/doi.org\/10.1021\/acs.jpcc.9b00913.","journal-title":"J Phys Chem C Nanomater Interfaces"},{"key":"3190_CR47","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jconrel.2011.07.031","volume":"157","author":"AO Elzoghby","year":"2012","unstructured":"Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012;157:168\u201382.","journal-title":"J Control Release"},{"key":"3190_CR48","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28\u201351.","journal-title":"Adv Drug Deliv Rev"},{"key":"3190_CR49","unstructured":"Clarke SP. Development of hierarchical magnetic nanocomposite materials for biomedical applications 2013. Doctoral dissertation, Dublin City University."},{"key":"3190_CR50","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/PHARMACEUTICS10020057","volume":"10","author":"M Danaei","year":"2018","unstructured":"Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics. 2018;10:57. https:\/\/doi.org\/10.3390\/PHARMACEUTICS10020057.","journal-title":"Pharmaceutics"},{"key":"3190_CR51","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.bmc.2011.07.048","volume":"20","author":"G Leriche","year":"2012","unstructured":"Leriche G, Chisholm L, Wagner A. Cleavable linkers in chemical biology. Bioorg Med Chem. 2012;20:571\u201382.","journal-title":"Bioorg Med Chem"},{"key":"3190_CR52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.colsurfb.2005.06.001","volume":"44","author":"Q Gan","year":"2005","unstructured":"Gan Q, Wang T, Cochrane C, McCarron P. Modulation of surface charge, particle size and morphological properties of chitosan\u2013TPP nanoparticles intended for gene delivery. Colloids Surf B Biointerfaces. 2005;44:65\u201373.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3190_CR53","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0168-3659(01)00294-2","volume":"73","author":"KA Janes","year":"2001","unstructured":"Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonso MJ. Chitosan nanoparticles as delivery systems for doxorubicin. J Control Release. 2001;73:255\u201367.","journal-title":"J Control Release"},{"key":"3190_CR54","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0378-5173(02)00548-3","volume":"250","author":"Y Xu","year":"2003","unstructured":"Xu Y, Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm. 2003;250:215\u201326.","journal-title":"Int J Pharm"},{"key":"3190_CR55","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1023\/A:1020404615898","volume":"19","author":"M Huang","year":"2002","unstructured":"Huang M, Ma Z, Khor E, Lim L-Y. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharm Res. 2002;19:1488\u201394.","journal-title":"Pharm Res"},{"key":"3190_CR56","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/smll.200901158","volume":"6","author":"A Verma","year":"2010","unstructured":"Verma A, Stellacci F. Effect of surface properties on nanoparticle\u2013cell interactions. Small. 2010;6:12\u201321.","journal-title":"Small"},{"key":"3190_CR57","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3390\/pharmaceutics13101686","volume":"13","author":"N Aibani","year":"2021","unstructured":"Aibani N, Rai R, Patel P, Cuddihy G, Wasan EK. Chitosan nanoparticles at the biological interface: implications for drug delivery. Pharmaceutics. 2021;13:1686.","journal-title":"Pharmaceutics"},{"key":"3190_CR58","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.2147\/IJN.S36111","volume":"7","author":"E Fr\u00f6hlich","year":"2012","unstructured":"Fr\u00f6hlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine. 2012;7:5577. https:\/\/doi.org\/10.2147\/IJN.S36111.","journal-title":"Int J Nanomedicine"},{"key":"3190_CR59","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3390\/PHARMACEUTICS13101686","volume":"13","author":"N Aibani","year":"2021","unstructured":"Aibani N, Rai R, Patel P, Cuddihy G, Wasan EK. Chitosan Nanoparticles at the Biological Interface: Implications for Drug Delivery. Pharmaceutics. 2021;13:1686. https:\/\/doi.org\/10.3390\/PHARMACEUTICS13101686.","journal-title":"Pharmaceutics"},{"key":"3190_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/J.NANO.2019.102073","volume":"21","author":"V Dur\u00e1n","year":"2019","unstructured":"Dur\u00e1n V, Yasar H, Becker J, Thiyagarajan D, Loretz B, Kalinke U, et al. Preferential uptake of chitosan-coated PLGA nanoparticles by primary human antigen presenting cells. Nanomedicine. 2019;21: 102073. https:\/\/doi.org\/10.1016\/J.NANO.2019.102073.","journal-title":"Nanomedicine"},{"key":"3190_CR61","doi-asserted-by":"publisher","DOI":"10.1088\/0957-4484\/26\/14\/145103","volume":"26","author":"E Fahrl\u00e4nder","year":"2015","unstructured":"Fahrl\u00e4nder E, Schelhaas S, Jacobs AH, Langer K. PEGylated human serum albumin (HSA) nanoparticles: preparation, characterization and quantification of the PEGylation extent. Nanotechnology. 2015;26: 145103.","journal-title":"Nanotechnology"},{"key":"3190_CR62","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2217\/nnm.11.19","volume":"6","author":"JV Jokerst","year":"2011","unstructured":"Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine. 2011;6:715\u201328.","journal-title":"Nanomedicine"},{"key":"3190_CR63","volume":"3","author":"G Shadambikar","year":"2021","unstructured":"Shadambikar G, Marathe S, Ji N, Almutairi M, Bandari S, Zhang F, et al. Formulation development of itraconazole PEGylated nano-lipid carriers for pulmonary aspergillosis using hot-melt extrusion technology. Int J Pharm X. 2021;3: 100074.","journal-title":"Int J Pharm X"},{"key":"3190_CR64","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3390\/pharmaceutics14051034","volume":"14","author":"S Marathe","year":"2022","unstructured":"Marathe S, Shadambikar G, Mehraj T, Sulochana SP, Dudhipala N, Majumdar S. Development of \u03b1-tocopherol succinate-based nanostructured lipid carriers for delivery of paclitaxel. Pharmaceutics. 2022;14:1034.","journal-title":"Pharmaceutics"},{"key":"3190_CR65","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.carbpol.2014.06.052","volume":"112","author":"A Guerry","year":"2014","unstructured":"Guerry A, Cottaz S, Fleury E, Bernard J, Halila S. Redox-stimuli responsive micelles from DOX-encapsulating polycaprolactone-g-chitosan oligosaccharide. Carbohydr Polym. 2014;112:746\u201352. https:\/\/doi.org\/10.1016\/j.carbpol.2014.06.052.","journal-title":"Carbohydr Polym"},{"key":"3190_CR66","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0928-0987(00)00169-X","volume":"12","author":"M Merodio","year":"2001","unstructured":"Merodio M, Arnedo A, Renedo MJ, Irache JM. Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties. Eur J Pharm Sci. 2001;12:251\u20139.","journal-title":"Eur J Pharm Sci"},{"key":"3190_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122761","volume":"635","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wang J, Xing H, Liu C, Li X. Redox-responsive paclitaxel-pentadecanoic acid conjugate encapsulated human serum albumin nanoparticles for cancer therapy. Int J Pharm. 2023;635: 122761. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.122761.","journal-title":"Int J Pharm"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03190-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03190-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03190-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T09:40:54Z","timestamp":1757238054000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03190-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":67,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["3190"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03190-9","relation":{},"ISSN":["1530-9932"],"issn-type":[{"type":"electronic","value":"1530-9932"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"192"}}